Our recent agreements


Global development and commercialization rights of elacestrant, an oral SERD currently being evaluated in the EMERALD Phase 3 study as hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer. Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.

Exclusive commercialization rights of NEXPOVIO (selinexor) in Europe, Latin America, and the CIS countries. Selinexor is a first-in-class oral Selective Inhibitor of Nuclear Export (SINE), approved in the US for multiple myeloma and under Accelerated Approval for diffuse large B-cell lymphoma and approved in the EU under a Conditional Marketing Authorization for multiple myeloma. Selinexor is being developed for the treatment of additional hematologic and solid tumor indications.

With this collaboration, we are one step closer toward fulfilling our mission to prolong patients’ lives.


Menarini strengthened its respiratory value proposition with various commercial deals in Asthma and COPD for GSK’s Ellipta’s Portfolio (LABA, LAMA, LAMA/LABA). In addition, Nucala® (mepolizumab) is also included for severe Asthma


Melinta and Menarini have entered into a commercial and co-development agreement for Quofenix®, Vaborem™, Orbactiv® and Minocin® in 68 countries, thus building a high value antinfectives platform.